On October 6, Illumina rose 5.01% in regular trading, trading at $305.46/share, with Turnover of $70.87 million. The move came after RBC Capital Markets raised its price target on the stock to $310 from $230, keeping an outperform rating.

RBC cited durable mid-teens growth in clinical sequencing revenue, driven by oncology volume growth and easing pricing headwinds. The firm also expects BioInsight and the Billion Cell Atlas to add 1 to 2 percentage points to growth in fiscal 2027, while academic research demand may bottom out that year. Recent target increases from Guggenheim, Leerink Partners, and Piper Sandler have further reinforced the bullish view.

Illumina, Inc. develops, manufactures, and markets life science tools and integrated systems for large-scale analysis of genetic variation and function. It serves genomic research centers, academic institutions, government laboratories, hospitals, and biotechnology and pharmaceutical companies worldwide.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)